NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.
Don't have an account? Subscribe
ADVERTISEMENT
ADVERTISEMENT
The HSE has officially unveiled a Managed Access Programme (MAP) for Delta-9-tetrahydrocannabinol/Cannabidiol (Sativex). The treatment is an anti-spasticity medication aimed at improving the quality-of-life for people living with multiple sclerosis (MS).
The programme is intended to provide much-needed relief for those living with moderate-to-severe MS-related spasticity, who have not adequately responded to other anti-spasticity medications.
MS Ireland has campaigned for some time for the medication to be made available in Ireland. Ms Ava Battles, Chief Executive of MS Ireland, stated: “This is wonderful news for the cohort of people living with MS who benefit from this treatment but have been struggling to self-fund or those who have been unable to access it due to the prohibitive costs.”
Consultant Neurologist Dr Hugh Kearney added: “Sativex will be an additional pharmacological treatment available for spasticity in MS. Our hope is that with better disease-modifying drugs for MS, we will see complications like spasticity much less often. This medication option may not suit everyone as it has many possible side effects, so other treatments such as physiotherapy and occupational therapy will still be as important as ever.”
The medication is an oromucosal spray contained in a 10 ml vial, with each 100-microlitre spray delivering 2.7 mg THC and 2.5 mg CBD from Cannabis sativa L. It is designed for adult patients with MS, offering symptom improvement where other treatments have failed. The MAP, which has been effective from 1 October, 2023, ensures reimbursement only for the licensed indication, as described in section 1.1 of the MAP guidelines.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
Michelle, a 46-year-old female, underwent biopsy of a lesion in her left sided chest musculature in...
Attendees of the upcoming Spring Meeting of the Irish Society for Rheumatology can expect a rich...
ADVERTISEMENT
The Judge's report proposes that a Tribunal be established under legislation to hear and determine claims...
In December, the HSE released part of an external review into the case of 'Brandon', a...
The evidence on doctor burnout “should scare us and concern us”, the Director of the RCSI...
A review of public health governance structures and addressing “longstanding” IT infrastructure...
ADVERTISEMENT
ADVERTISEMENT
Leave a Reply
You must be logged in to post a comment.